Skip to main content

Juan Luis Restrepo Vera

Institutions of which they are part

Predoctoral researcher
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Juan Luis Restrepo Vera

Institutions of which they are part

Predoctoral researcher
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Projects

Models d'estudi de malalties degudes a manteniment defectuós del DNA mitocondrial

IP: Ramon Martí Seves
Collaborators: Mª Jesus Melia Grimal, Pau Mollá Zaragozá, Javier Francisco Ramón Pasías, Juan Luis Restrepo Vera
Funding agency: Instituto de Salud Carlos III
Funding: 208750
Reference: PI24/00838
Duration: 01/01/2025 - 31/12/2027

Células progenitoras residentes derivadas de músculo esquelético: modelo celular in vitro preferente en el proceso diagnóstico y de investigación traslacional de las enfermedades mitocondriales primarias

IP: Ramon Martí Seves
Collaborators: Juan Luis Restrepo Vera, Laia Perez Lasarte
Funding agency: Fundació Institut de Recerca HUVH
Funding: 35000
Reference: CARLESM/RAMON_MS
Duration: 30/06/2023 - 29/06/2024

Células progenitoras residentes derivadas de músculo esquelético: modelo celular in vitro preferente en el proceso diagnóstico y de investigación traslacional de las enfermedades mitocondriales primarias

IP: Ramon Martí Seves
Collaborators: Juan Luis Restrepo Vera
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 74452.89
Reference: 2024 FI-1 00388
Duration: 01/07/2024 - 30/06/2025

USO DE MARCADORES EN LA DETECCIÓN DE CRISIS EPILÉPTICAS DE MAL PRONÓSTICO

IP: Estevo Santamarina Pérez
Collaborators: Maria Sueiras Gil, Elena Fonseca Hernandez, Juan Luis Restrepo Vera, Manuel Quintana Luque
Funding agency: Instituto de Salud Carlos III
Funding: 73810
Reference: PI19/01575
Duration: 01/01/2020 - 30/06/2024

Related news

The projects, selected under the 2026 Health Research and CaixaImpulse Health Innovation calls, address topics ranging from new therapies for childhood neurological disorders and Parkinson’s disease to the treatment of mitochondrial diseases and cancer.

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

Related professionals

Maria Ruoxuan Crespi Amer

Maria Ruoxuan Crespi Amer

Predoctoral researcher
Clinical Neuroimmunology
Read more
Hajar Tourabi

Hajar Tourabi

External Strategy Directorate
Read more
Yeika Adelina Perez Dotel

Yeika Adelina Perez Dotel

Research technician
Rheumatology
Read more
Olivia Casbas Recuenco

Olivia Casbas Recuenco

Predoctoral researcher
Diabetes and Metabolism
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.